

Biocure Corporate Update and Financing

VANCOUVER, British Columbia, December 2nd, 2021 -- Biocure Technology Corp. ("Biocure" or the "Company") (CSE:CURE; OTCQB: BICTF) is pleased to provide the following operational and investment update to the market and its stakeholders.

The Company continues to build financial value within Cancer Treatment through two ways;

- Development of its own pipeline products with potential for the Company to secure a number of patents covering revolutionary Car-T bi-specific therapies in the near term.
- Building value through partnering with strategic players and licencees (non-dilutive funding).

1. **Company Focus and near-term Patent Potential** - The Company is currently focused on two kinds of innovative CAR-T pipelines covering numerous types of cancer treatment.

- i. Chronic Lymphocytic Leukemia ("CLL") - Bi-specific CAR-T for regulation system of immune check point inhibitor. BiocurePharm Korea ("BPK") is developing a revolutionary bi-specific CAR-T with a unique gene structure for the treatment of CLL. BPK has confirmed the CAR-T configurations and the working conditions of major components and as such plans to enter into the evaluation stage by creating a complete CAR-T form. BPK is excited with this potentially game-changing therapy treatment and targets to submit the patent application by the end of Q1, 2022.
- ii. Lung and Ovarian cancer - Bi-specific new CAR-T. Based on the bi-specific dual CAR-T, first in class CAR-T development that can regulate Tumor Immune Microenvironment ("TME") in specific conditions of cancer cells is in progress. BPK has confirmed that the TME control system is working under this specific condition and plans to file a patent application upon completing dual CAR-T form. The Company is planning to begin preclinical trials in Q2, 2022 with clinical trials commencing thereafter.
- iii. Innovative dual CAR-T for lung cancer BPK is developing a powerful innovative CAR-T by combining two types of new CAR-T which the Company expects to demonstrate excellent therapeutic effectiveness. This innovative CAR-T for solid tumor has the potential for both immune regulation function and TME control function. This CAR-T will be able to create a new IP, and it is expected to play a groundbreaking role in cancer treatment using cell therapy.

2. **Strategic Partnerships and Licensing (non-dilutive financing)** – The Company has received strong interest from Technology-based Industry experts and Academic institutes regarding potential partnership to leverage and develop multiple new therapies.

- i. BPK is in advanced collaboration discussions with a number of Strategic Industry players in Europe and Korea regarding development of a new CAR-T form using nanobody and new immune regulation factors.
- ii. BPK has additionally been in cooperation with a number of academic institutes focused on further development of its CAR-T therapies.

3. **Solid Pipeline of future trials**

The Company is in discussions with a number of groups regarding planned trials in the medium term (12 months) including;

- i. A clinical trial planned in Germany with a team of CLL specialists.
- ii. A clinical trial in Korea targeting lung cancer including multi-national clinical trials in Australia and Singapore.

4. Strategic Partnerships and Investment

The Company has received strong interest out of Europe and Korea from a number of groups regarding potential strategic partnership and investment to leverage the enormous potential value of these therapies. The company is currently evaluating these proposals and will further update the market as these discussions progress.

Biocure has closed its non-brokered private placement through its Korean Subsidiary BiocurePharm, Korea (“BPK”), BPK has issued 7,692 shares at 13.897 CAD per share for gross proceeds of \$106,896. Finder’s fee shall be payable upon the closing. All dollar values are based on the published Exchange Rate of CAD0.001069/KRW1 on November 29, 2021, Bank of Canada. After the issuance of new BPK shares, CURE holds now 94.13% interest in BPK valuing BPK at approx. 53 million CAD.

The net proceeds from the non-brokered private placement are intended to be used for general working capital and development of CAR T in Korea.

About Biocure

Biocure is a leading biotech company developing its CAR-T cell therapy for leukemia, lung, breast and pancreatic cancer. Biocure, headquartered in Korea, has joint venture partners in Asia and Europe with planned clinical trials commencing in 2021. Biocure is in the process of pre-clinical trials of five major biosimilar products in South Korea, including Interferon Beta 1b, PEG- Filgrastim as well as Ranibizumab. Interferon Beta 1b is used for treating relapsing forms of multiple sclerosis (“MS”) Filgrastim is used to treat neutropenia, a lack of certain white blood cells caused by bone marrow transplants, chemotherapy, and other conditions. Ranibizumab is used for treating macular degeneration. It is also used to treat a type of eye problem known as macular edema, as well as certain eye problems caused by diabetes.

ON BEHALF OF THE BOARD OF DIRECTORS

/S/ “SANG MOK LEE”

CEO and Director

For further information, please contact:

Biocure Technology Inc. Telephone: 604-609-7146, or info@biocuretech.com (mailto:info@biocuretech.com)



Press release on PDF (/images/SEDAR/CURE_-_Corporate_Update__Financing_NR_Dec_2_2021_Final_.pdf)

Certain statements in this news release, which are not historical in nature, constitute “forward looking statements” within the meaning of that phrase under applicable Canadian securities law. These statements include, but are not limited to, statements or information concerning the Company’s proposed activities under the Agreement and the expectations of the Company regarding funding payments due pursuant to the Agreement. These statements reflect management’s current assumptions and expectations and by their nature are subject to certain underlying assumptions, known and unknown risks and uncertainties and other factors which may cause actual results, performance or events to be materially different from those expressed or implied by such forward looking statements. Except as required pursuant to applicable securities laws, the Company will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by the Company. Readers are cautioned not to

place undue reliance on forward looking statements. Neither the Canadian Securities Exchange (the "CSE") nor the Investment Industry Regulatory Organization of Canada) accepts responsibility for the adequacy or accuracy of this release.